Analysts Offer Insights on Healthcare Companies: Stericycle (SRCL), Biogen (BIIB) and Acadia Healthcare (ACHC)
Biogen Price Target Maintained With a $340.00/Share by RBC Capital
Biogen Price Target Maintained With a $340.00/Share by RBC Capital
Research Alert: CFRA Maintains Hold Opinion On Shares Of Biogen Inc.
CFRA, an independent research provider, has provided MT Newswires with the following research alert. Analysts at CFRA have summarized their opinion as follows: We lift our target by $25 to $314, 18.7x
RBC Capital Reiterates Outperform on Biogen, Maintains $340 Price Target
RBC Capital analyst Brian Abrahams reiterates Biogen (NASDAQ:BIIB) with a Outperform and maintains $340 price target.
Biogen's (NASDAQ:BIIB) Investors Will Be Pleased With Their Notable 52% Return Over the Last Year
If you want to compound wealth in the stock market, you can do so by buying an index fund. But you can significantly boost your returns by picking above-average stocks. For example, the Biogen Inc.
Goldman Sachs Remains a Buy on Biogen (BIIB)
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
Biogen stock jumped into a buy zone Thursday after Medicare officials said they would reimburse patients for the cost of Alzheimer's treatments that target an abnormal protein called beta amyloid. The
Medicare Will Pay for Biogen's Alzheimer's Drug, With a Caveat -- Barrons.com
By Josh Nathan-Kazis Medicare will pay for fully approved Alzheimer's disease therapies for patients whose doctors submit data on their treatment to a nationwide registry, the agency that oversees th
Biogen (BIIB) Receives a Buy From Mizuho Securities
Piper Sandler Increases Price Target on Biogen to $360 From $346, Maintains Overweight Rating
Biogen (BIIB) has an average outperform rating and price target range of $263 to $398, according to analysts polled by Capital IQ. Price: 305.54, Change: +9.13, Percent Change: +3.08
Medicare to Cover Alzheimer's Drugs Granted Full FDA Approval
Express News | Biogen Is Maintained at Overweight by Piper Sandler
Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler
Biogen Price Target Raised to $360.00/Share From $346.00 by Piper Sandler
Piper Sandler Maintains Overweight on Biogen, Raises Price Target to $360
Piper Sandler analyst Christopher Raymond maintains Biogen (NASDAQ:BIIB) with a Overweight and raises the price target from $346 to $360.
Biogen Unusual Options Activity For May 26
Someone with a lot of money to spend has taken a bullish stance on Biogen (NASDAQ:BIIB).And retail traders should know.We noticed this today when the big position showed up on publicly available optio
Elon Musk's Neuralink Gets FDA Nod to Start Human Trial of Brain Implant
Analyst Ratings for Biogen
Within the last quarter, Biogen (NASDAQ:BIIB) has observed the following analyst ratings: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings95700Last 30D001001M Ago534002M Ago22200
Analysts Offer Insights on Healthcare Companies: Sanofi (OtherSNYNF), Biogen (BIIB) and Blueprint Medicines (BPMC)
Express News | Biogen Price Target Maintained With a $263.00/Share by Wedbush
Wedbush Reiterates Neutral on Biogen, Maintains $263 Price Target
Wedbush analyst Laura Chico reiterates Biogen (NASDAQ:BIIB) with a Neutral and maintains $263 price target.
No matches yet
Operations too frequent. Please try again later.
Please check network settings and try again Refresh Refresh
Loading
History record 
Quotes All >
News All >